全文获取类型
收费全文 | 53865篇 |
免费 | 3750篇 |
国内免费 | 133篇 |
专业分类
耳鼻咽喉 | 433篇 |
儿科学 | 1977篇 |
妇产科学 | 1846篇 |
基础医学 | 6497篇 |
口腔科学 | 1009篇 |
临床医学 | 9084篇 |
内科学 | 9940篇 |
皮肤病学 | 835篇 |
神经病学 | 4754篇 |
特种医学 | 1041篇 |
外国民族医学 | 33篇 |
外科学 | 4702篇 |
综合类 | 726篇 |
一般理论 | 80篇 |
预防医学 | 7389篇 |
眼科学 | 637篇 |
药学 | 3030篇 |
1篇 | |
中国医学 | 138篇 |
肿瘤学 | 3596篇 |
出版年
2023年 | 325篇 |
2022年 | 458篇 |
2021年 | 1150篇 |
2020年 | 766篇 |
2019年 | 1169篇 |
2018年 | 1383篇 |
2017年 | 934篇 |
2016年 | 1055篇 |
2015年 | 1190篇 |
2014年 | 1617篇 |
2013年 | 2591篇 |
2012年 | 3698篇 |
2011年 | 3961篇 |
2010年 | 2147篇 |
2009年 | 1966篇 |
2008年 | 3453篇 |
2007年 | 3886篇 |
2006年 | 3719篇 |
2005年 | 3585篇 |
2004年 | 3439篇 |
2003年 | 3271篇 |
2002年 | 3087篇 |
2001年 | 448篇 |
2000年 | 343篇 |
1999年 | 456篇 |
1998年 | 712篇 |
1997年 | 559篇 |
1996年 | 485篇 |
1995年 | 393篇 |
1994年 | 405篇 |
1993年 | 393篇 |
1992年 | 294篇 |
1991年 | 252篇 |
1990年 | 239篇 |
1989年 | 201篇 |
1988年 | 202篇 |
1987年 | 223篇 |
1986年 | 179篇 |
1985年 | 208篇 |
1984年 | 222篇 |
1983年 | 222篇 |
1982年 | 281篇 |
1981年 | 252篇 |
1980年 | 200篇 |
1979年 | 145篇 |
1978年 | 126篇 |
1977年 | 141篇 |
1976年 | 122篇 |
1975年 | 100篇 |
1973年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
41.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
42.
43.
44.
45.
46.
Bradley J Catalone Shendra R Miller Mary Lee Ferguson Dan Malamud Tina Kish-Catalone Nina J Thakkar Fred C Krebs Mary K Howett Brian Wigdahl 《Biomedicine & Pharmacotherapy》2005,59(8):430-437
C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity. 相似文献
47.
48.
A R Dias R N Melo O C E Gebara E A D'Amico A Nussbacher H W Halbe J A Pinotti 《Climacteric》2005,8(1):63-70
OBJECTIVES: To compare the effect of conjugated equine estrogens (CEE) and raloxifene on lipid profile and hemostasis. MATERIALS AND METHODS: A double-blind, randomized and parallel study was performed with 90 healthy postmenopausal women, aged 54 +/- 5 years, divided into three groups and submitted to daily therapy with either CEE 0.625 mg, raloxifene 60 mg or placebo for 4 months. The lipid profile, coagulation and fibrinolytic factors were analyzed. RESULTS: CEE increased the levels of high density lipoprotein cholesterol (HDL-C) from 49.0 to 56.8 mg/dl (p < 0.001), very low density lipoprotein cholesterol (VLDL-C) from 17.2 to 22.3 mg/dl (p < 0.001), and triglycerides from 86.0 to 111.7 mg/dl (p < 0.001), and decreased the levels of low density lipoprotein cholesterol (LDL-C) from 121.0 to 106.5 mg/dl (p < 0.001). The only significant effect of raloxifene was an increase in the levels of HDL-C from 46.0 to 47.8 mg/dl (p = 0.019). There was no significant reduction in LDL-C, from 115.5 to 110.2 mg/dl (p = 0.06), VLDL-C, from 21.7 to 20.0 mg/dl (p = 0.201), and triglycerides, from 108 to 100 mg/dl (p = 0.201). CEE decreased the levels of fibrinogen, from 370.5 to 326.8 g/l (p = 0.039) and the levels of antithrombin III, from 99.5 to 93.2% (p < 0.001). Raloxifene decreased the levels of fibrinogen, from 354.7 to 302.0 g/l (p = 0.009) and the levels of antithrombin III, from 102.4 to 98.5% (p = 0.039). CEE increased levels of protein C from 103.7 to 115.3 mg/l (p < 0.001) and raloxifene did not change the levels of protein C (107.9 to 105.1 mg/l; p = 0.158). CEE decreased the antigen levels of tissue plasminogen activator (t-PA) from 8.8 to 6.8 U/ml (p < 0.001), and of plasminogen activator inhibitor (PAI-1) from 30.8 to 21.6 U/ml (p < 0.010), whereas raloxifene had no significant effect on either t-PA, from 9.6 to 9.2 U/ml (p = 0.235) or PAI-1 antigen levels, from 32.1 to 30.4 U/ml (p = 0.538). CONCLUSION Both CEE and raloxifene exert significant effects on the lipid and coagulation profile. CEE had a more significant effect on fibrinolysis than raloxifene. These effects may have a significant impact on the cardiovascular risk that needs to be confirmed in larger studies. 相似文献
49.
50.
Coronary artery bypass grafts: visualization with MR imaging 总被引:1,自引:0,他引:1